Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

CXCL9 and CXCL11 Levels in Patients With Autoimmune Thyroiditis and Habitual Abortions

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2012 by Ankara Education and Research Hospital.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Ankara Education and Research Hospital
ClinicalTrials.gov Identifier:
NCT01644318
First received: July 17, 2012
Last updated: July 18, 2012
Last verified: July 2012
  Purpose

The purpose of this study is to measure serum CXCL9 and CXCL11 levels in patients with autoimmune thyroiditis and habitual abortions


Condition
Habitual Abortion

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional

Resource links provided by NLM:


Further study details as provided by Ankara Education and Research Hospital:

Primary Outcome Measures:
  • Serum CXCL9 and CXCL11 levels in patients with autoimmune thyroiditis and habitual abortions

Groups/Cohorts
authoimmıne thyroiditis and habitual abortus
authoimmune thyroiditis
healthy controls

  Eligibility

Ages Eligible for Study:   20 Years to 40 Years
Genders Eligible for Study:   Female
Sampling Method:   Probability Sample
Study Population

Endocrinology Outpatient Clinic

Criteria

Inclusion Criteria:

  • non-pregnant women with euthyroid autoimmune thyroiditis and a history of first trimester recurrent spontaneous abortions

Exclusion Criteria:

  • 1) presence of acute or chronic systemic diseases; 2) other autoimmune diseases; 3) pregnancy and lactation over the previous 6 months; 4) evidence of infectious diseases in the last 3 months; 5) treatment with drugs known to interfere with cytokine release, such as corticosteroids, immunosuppressors, or nonsteroidal antiinflammatory drugs, amiodarone, and lithium; 6) clinical history of hyperthyroidism and/or the presence of anti-TSH receptor antibodies.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01644318

Locations
Turkey
Ankara Education and Research Hospital
Ankara, Turkey, 06340
Sponsors and Collaborators
Ankara Education and Research Hospital
  More Information

No publications provided by Ankara Education and Research Hospital

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT01644318     History of Changes
Other Study ID Numbers: 3848
Study First Received: July 17, 2012
Last Updated: July 18, 2012
Health Authority: Turkey: Ethics Committee

Additional relevant MeSH terms:
Abortion, Habitual
Abortion, Spontaneous
Pregnancy Complications

ClinicalTrials.gov processed this record on November 25, 2014